Strategies for Preservation of Ovarian and Testicular Function after Immunosuppression

American Journal of Kidney Diseases

Volumn 43, Issue 5, 2004, Pages 772-781

  Pendse, Shona ^a   Ginsburg, Elizabeth ^a   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytotoxic agents; Glomerulonephritis; Immunosuppression; Infertility; Ovarian function; Testicular function

Indexed keywords

CYCLOPHOSPHAMIDE; GONADORELIN; TESTOSTERONE;

CELL TRANSPLANTATION; CRYOPRESERVATION; DOSE RESPONSE; DRUG METABOLISM; DRUG SCREENING; FEMALE; GERM CELL; GLOMERULOPATHY; GONADAL DISEASE; HORMONAL THERAPY; HUMAN; ILLNESS BEHAVIOR; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; MALE; MEDICAL DECISION MAKING; NONHUMAN; OOCYTE; OVARY FUNCTION; REVIEW; SPERM; TESTIS FUNCTION;

EID: 1942434758     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.01.008     Document Type: Review

References (94)

1. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR: Preserving ovarian function in patients receiving cyclophosphamide. Lupus 8:3-10, 1999
2. Howell S, Shalet S: Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27:927-943, 1998
3. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 91:613-621, 2001
4. Nicosia SV, Matus-Ridley M, Meadows AT: Gonadal effects of cancer therapy in girls. Cancer 55:2364-2372, 1985
5. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG: The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 49:418-422, 1982
6. Masala A, Faedda R, Alagna S, et al: Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126:292-295, 1997
7. Kobayashi H, Urashima M, Hoshi Y, et al: Testicular morphological changes in children with acute lymphoblastic leukemia following chemotherapy. Acta Paediatr Jpn 38:640-643, 1996
8. Holmes SJ, Whitehouse RW, Clark ST, Crowther DC, Adams JE, Shalet SM: Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer 70:371-375, 1994
9. Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH: Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. Bone Marrow Transplant 13:519-522, 1994
10. Byrne J, Fears TR, Gail MH, et al: Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 166:788-793, 1992
11. Balow JE, Austin HA III, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH: NIH conference. Lupus nephritis. Ann Intern Med 106:79-94, 1987
12. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977
13. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-369, 1993
14. Boddy AV, Yule SM: Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38:291-304, 2000
15. Busse D, Busch FW, Bohnenstengel F, et al: Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 15:1885-1896, 1997
16. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495-1501, 2002
17. Haubitz M, Schellong S, Gobel U, et al: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 41:1835-1844, 1998
18. Grochow LB, Colvin M: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4:380-394, 1979
19. Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20:194-208, 1991
20. Bagley CM Jr, Bostick FW, DeVita VT Jr: Clinical pharmacology of cyclophosphamide. Cancer Res 33:226-233, 1973
21. Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19:443-451, 1981
22. Mouridsen HT, Jacobsen E: Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh) 36:409-414, 1975
23. Bramwell V, Calvert RT, Edwards G, Scarffe H, Crowther D: The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 3:253-259, 1979
24. Wang LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in an hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 29:365-372, 1981
25. Wagner T, Heydrich D, Bartels H, Hohorst HJ: [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites]. Arzneimittelforschung 30:1588-1592, 1980
26. Langevitz P, Klein L, Pras M, Many A: The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 28:157-158, 1992
27. Ataya K, Moghissi K: Chemotherapy-induced premature ovarian failure: Mechanisms and prevention. Steroids 54:607-626, 1989
28. Blumenfeld Z, Avivi I, Ritter M, Rowe JM: Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 6:229-239, 1999
29. Blumenfeld Z, Haim N: Prevention of gonadal damage during cytotoxic therapy. Ann Med 29:199-206, 1997
30. Gradishar WJ, Schilsky RL: Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 16:425-436, 1989
31. Warne GL, Fairley KF, Hobbs JB, Martin FI: Cyclophosphamide-induced ovarian failure. N Engl J Med 289:1159-1162, 1973
32. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M: Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9:401-405, 2000
33. Oktay K, Newton H, Aubard Y, Salha O, Gosden RG: Cryopreservation of immature human oocytes and ovarian tissue: An emerging technology? Fertil Steril 69:1-7, 1998
34. Blumenfeld Z, Amit T, Barkey RJ, Lunenfeld B, Brandes JM: Synergistic effect of growth hormone and gonadotropins in achieving conception in "clonidine-negative" patients with unexplained infertility. Ann N Y Acad Sci 626:250-265, 1991
35. Blumenfeld Z, Barkey RJ, Youdim MB, Brandes JM, Amit T: Growth hormone (GH)-binding protein regulation by estrogen, progesterone, and gonadotropins in human: The effect of ovulation induction with menopausal gonadotropins, GH, and gestation. J Clin Endocrinol Metab 75:1242-1249, 1992
36. Mandelbaum J, Junca AM, Plachot M, et al: Cryopreservation of human embryos and oocytes. Hum Reprod 3:117-119, 1988
37. Trounson A: Preservation of human eggs and embryos. Fertil Steril 46:1-12, 1986
38. Hunter JE, Bernard A, Fuller B, Amso N, Shaw RW: Fertilization and development of the human oocyte following exposure to cryoprotectants, low temperatures and cryopreservation: A comparison of two techniques. Hum Reprod 6:1460-1465, 1991
39. Trounson A, Kirby C: Problems in the cryopreservation of unfertilized eggs by slow cooling in dimethyl sulfoxide. Fertil Steril 52:778-786, 1989
40. Vincent C, Pickering SJ, Johnson MH: The hardening effect of dimethylsulphoxide on the mouse zona pellucida requires the presence of an oocyte and is associated with a reduction in the number of cortical granules present. J Reprod Fertil 89:253-259, 1990
41. Oktay K, Newton H, Mullan J, Gosden RG: Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 13:1133-1138, 1998
42. Oktay K, Buyuk E: The potential of ovarian tissue transplant to preserve fertility. Expert Opin Biol Ther 2:361-370, 2002
43. Jericho H, Wilton L, Gook DA, Edgar DH: A modified cryopreservation method increases the survival of human biopsied cleavage stage embryos. Hum Reprod 18:568-571, 2003
44. Van den Abbeel E, Camus M, Van Waesberghe L, Devroey P, Van Steirteghem AC: Viability of partially damaged human embryos after cryopreservation. Hum Reprod 12:2006-2010, 1997
45. Burns WN, Gaudet TW, Martin MB, et al: Survival of cryopreservation and thawing with all blastomeres intact identifies multicell embryos with superior frozen embryo transfer outcome. Fertil Steril 72:527-532, 1999
46. Edgar DH, Bourne H, Speirs AL, McBain JC: A quantitative analysis of the impact of cryopreservation on the implantation potential of human early cleavage stage embryos. Hum Reprod 15:175-179, 2000
47. Gook DA, Edgar DH, Stem C: The effects of cryopreservation regimens on the morphology of human ovarian tissue. Mol Cell Endocrinol 169:99-103, 2000
48. Gook DA, Edgar DH, Stem C: Effect of cooling rate and dehydration regimen on the histological appearance of human ovarian cortex following cryopreservation in 1,2-propanediol. Hum Reprod 14:2061-2068, 1999
49. Oktay K, Kan MT, Rosenwaks Z: Recent progress in oocyte and ovarian tissue cryopreservation and transplantation. Curr Opin Obstet Gynecol 13:263-268, 2001
50. Candy CJ, Wood MJ, Whittingham DG, Merriman JA, Choudhury N: Cryopreservation of immature mouse oocytes. Hum Reprod 9:1738-1742, 1994
51. Oktay K, Karlikaya GG, Aydin BA: Ovarian cryopreservation and transplantation: Basic aspects. Mol Cell Endocrinol 169:105-108, 2000
52. Eppig JJ, O'Brien MJ: Development in vitro of mouse oocytes from primordial follicles. Biol Reprod 54:197-207, 1996
53. O'Brien MJ, Pendola JK, Eppig JJ: A revised protocol for in vitro development of mouse oocytes from primordial follicles dramatically improves their developmental competence. Biol Reprod 68:1682-1686, 2003
54. Carroll J, Gosden RG: Transplantation of frozen-thawed mouse primordial follicles. Hum Reprod 8:1163-1167, 1993
55. Averette HE, Boike GM, Jarrell MA: Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin 40:199-209, 1990
56. Rivkees SA, Crawford JD: The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259:2123-2125, 1988
57. Ortin TT, Shostak CA, Donaldson SS: Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience. Int J Radiat Oncol Biol Phys 19:873-880, 1990
58. Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH: Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 21:333-339, 1993
59. Bakchine H, Brauner R, Thibaud E, et al: [Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease]. Arch Fr Pediatr 43:611-616, 1986
60. Kreuser ED, Hetzel WD, Billia DO, Thiel E: Gonadal toxicity following cancer therapy in adults: Significance, diagnosis, prevention and treatment. Cancer Treat Rev 17:169-175, 1990
61. Kreuser ED, Felsenberg D, Behles C, et al: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 3:S105-S110, 1992 (suppl 4)
62. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ: A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45:3651-3656, 1985
63. Ataya K, Rao LV, Lawrence E, Kimmel R: Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52:365-372, 1995
64. Ataya KM, Valeriote FA, Ramahi-Ataya AJ: Effect of cyclophosphamide on the immature rat ovary. Cancer Res 49:1660-1664, 1989
65. Ataya K, Tadros M, Ramahi A: Gonadotropin-releasing hormone agonist inhibits physiologic ovarian follicular loss in rats. Acta Endocrinol (Copenh) 121:55-60, 1989
66. Ataya KM, Palmer KC, Blacker CM, Moghissi KS, Mohammad SH: Inhibition of rat ovarian [3H]thymidine uptake by luteinizing hormone-releasing hormone agonists: A possible mechanism for preventing damage by cytotoxic agents. Cancer Res 48:7252-7256, 1988
67. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620-1626, 1996
68. Metcalfe W, Boulton-Jones JM: Exacerbation of lupus nephritis in association with leuprorelin injection for uterine leiomyoma. Nephrol Dial Transplant 12:1699-1700, 1997
69. Casoli P, Tumiati B, La Sala G: Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 24:1639-1640, 1997
70. Miyagawa S, Shirai T, Shimamoto I, Ichijo M, Ueki H: Worsening of systemic lupus erythematosus-associated thrombocytopenia after administration of gonadotropin-releasing hormone analog. Arthritis Rheum 37:1708-1709, 1994
71. Jacobson JD: Gonadotropin-releasing hormone: Potential role in autoimmunity. Int Immunopharmacol 1:1077-1083, 2001
72. Jacobson JD: Gonadotropin-releasing hormone and G proteins: Potential roles in autoimmunity. Ann N Y Acad Sci 917:809-818, 2000
73. Jacobson JD, Ansari MA, Kinealy M, Muthukrishnan V: Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: Potential role of G alpha(q/11). Endocrinology 140:3429-3437, 1999
74. Morton TL, Ansari MA, Jacobson JD: Gender differences and hormonal modulation of G proteins Galpha(q/11) expression in lymphoid organs. Neuroendocrinology 78:147-153, 2003
75. Radford JA, Lieberman BA, Brison DR, et al: Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 357:1172-1175, 2001
76. Gosden RG, Baird DT, Wade JC, Webb R: Restoration of fertility to oophorectomized sheep by ovarian autografts stored at - 196°C. Hum Reprod 9:597-603, 1994
77. Harp R, Leibach J, Black J, Keldahl C, Karow A: Cryopreservation of murine ovarian tissue. Cryobiology 31:336-343, 1994
78. Liu J, Van der Elst J, Van den Broecke R, Dhont M: Live offspring by in vitro fertilization of oocytes from cryopreserved primordial mouse follicles after sequential in vivo transplantation and in vitro maturation. Biol Reprod 64:171-178, 2001
79. Kim SS, Radford J, Harris M, et al: Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod 16:2056-2060, 2001
80. Oktay K: Ovarian tissue cryopreservation and transplantation: Preliminary findings and implications for cancer patients. Hum Reprod Update 7:526-534, 2001
81. Baird DT, Webb R, Campbell BK, Harkness LM, Gosden RG: Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at - 196° life as get a sense of those this a family that enthesopathy they say that the C. Endocrinology 140:462-471, 1999
82. Aubard Y, Piver P, Cogni Y, Fermeaux V, Poulin N, Driancourt MA: Orthotopic and heterotopic autografts of frozen-thawed ovarian cortex in sheep. Hum Reprod 14:2149-2154, 1999
83. Nugent D, Newton H, Gallivan L, Gosden RG: Protective effect of vitamin E on ischaemia-reperfusion injury in ovarian grafts. J Reprod Fertil 114:341-346, 1998
84. Ranganathan P, Mahran AM, Hallak J, Agarwal A: Sperm cryopreservation for men with nonmalignant, systemic diseases: A descriptive study. J Androl 23:71-75, 2002
85. Royere D, Barthelemy C, Hamamah S, Lansac J: Cryopreservation of spermatozoa: A 1996 review. Hum Reprod Update 2:553-559, 1996
86. Chapman RM, Sutcliffe SB, Malpas JS: Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA 245:1323-1328, 1981
87. Aboulghar MA, Mansour RT, Serour GI, et al: Fertilization and pregnancy rates after intracytoplasmic sperm injection using ejaculate semen and surgically retrieved sperm. Fertil Steril 68:108-111, 1997
88. Bogdanovic R, Banicevic M, Cvoric A: Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: Long-term follow-up study. Pediatr Nephrol 4:451-454, 1990
89. Ward JA, Robinson J, Furr BJ, Shalet SM, Morris ID: Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 50:568-574, 1990
90. Delic JI, Bush C, Peckham MJ: Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. Cancer Res 46:1909-1914, 1986
91. Pogach LM, Lee Y, Gould S, Giglio W, Huang HF: Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration. Cancer Res 48:4354-4360, 1988
92. Kurdoglu B, Wilson G, Parchuri N, Ye WS, Meistrich ML: Protection from radiation-induced damage to spermato-genesis by hormone treatment. Radiat Res 139:97-102, 1994
93. Meistrich ML, Parchuri N, Wilson G, Kurdoglu B, Kangasniemi M: Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J Androl 16:334-341, 1995
94. Brinster RL, Zimmermann JW: Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci U S A 91:11298-11302, 1994